Materials and methods
NSCLC, death, Tumor, tumor
DISEASE PROGRESSION, TUMOR, TUMOR, NSCLC
The ALEX study design has been published previously [Tumor assessment consisted at minimum of a computed tomography or magnetic resonance imaging scan at baseline. Clinical lesions were assessed with caliper measurement and documented by color photography, including a ruler to estimate the size of the lesion. Tumor assessments were carried out in all patients at baseline and every 8 weeks until disease progression or death. Longitudinal tumor size data, defined as the sum of the longest diameters (SLD) of target lesions at each visit according to RECIST 1.1, were used for the estimation of TGI metrics. Patients with at least baseline and one post-baseline tumor size measurements were defined as evaluable, and data from patients who only had baseline tumor assessments were excluded from the analysis.The previously published biexponential TGI [The model was implemented as a nonlinear mixed-effect model [The OS data from ALEX study were used to externally validate the historical TGI-OS model developed across all atezolizumab NSCLC studies [